Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Significant Decline in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 791,500 shares, a decrease of 35.1% from the May 15th total of 1,220,000 shares. Approximately 4.8% of the company’s shares are sold short. Based on an average trading volume of 1,240,000 shares, the days-to-cover ratio is currently 0.6 days.

Xilio Therapeutics Price Performance

Shares of XLO stock opened at $0.67 on Wednesday. The stock has a market capitalization of $34.44 million, a PE ratio of -0.79 and a beta of -0.01. The business’s 50 day simple moving average is $0.78 and its 200 day simple moving average is $0.87. Xilio Therapeutics has a one year low of $0.62 and a one year high of $1.70.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.28). Xilio Therapeutics had a negative net margin of 585.54% and a negative return on equity of 262.69%. The firm had revenue of $2.93 million during the quarter, compared to the consensus estimate of $42.00 million. As a group, research analysts expect that Xilio Therapeutics will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On Xilio Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of XLO. ADAR1 Capital Management LLC acquired a new stake in shares of Xilio Therapeutics during the 1st quarter worth approximately $29,000. Aptus Capital Advisors LLC acquired a new stake in Xilio Therapeutics in the fourth quarter worth $39,000. Raymond James Financial Inc. bought a new stake in Xilio Therapeutics in the fourth quarter valued at $48,000. Avantax Planning Partners Inc. acquired a new position in shares of Xilio Therapeutics during the first quarter valued at about $109,000. Finally, Trustees of Columbia University in the City of New York bought a new position in shares of Xilio Therapeutics during the 4th quarter worth about $238,000. Institutional investors and hedge funds own 54.29% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Xilio Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.